<DOC>
	<DOCNO>NCT02869984</DOCNO>
	<brief_summary>Poor functional outcome report inevitably , 90 % patient experience bowel habit change sphincter-saving surgery rectal cancer . But , currently specific treatment ARS symptom base empirical management try Recently , 5-HT3 receptor antagonist use treatment IBS-D , reveal slow bowel movement improve stool consistency urgency . We perform clinical trial use ramosetron ( IrribowÂ® ) treatment ARS</brief_summary>
	<brief_title>Clinical Trial Assessing 5-HT3 Receptor Antagonist ( Ramosetron ) Treatment Anterior Resection Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Ramosetron</mesh_term>
	<criteria>The patient undergo sphincter save surgery rectal cancer recur rectal cancer rectal cancer distant metastasis permanent stoma formation postoperative concurrent chemoradiotherapy uncontrolled medical disease inflammatory bowel disease uncontrolled constipation preoperative incontinence ( LARS score , 20 ) allergic intervention drug</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>